Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion type Assertion NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_head.
- NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion description "[Part II of this continuing medical education article will discuss the treatment options for stage IV melanoma, including novel therapies, such as ipilimumab and vemurafenib; established therapies, including high-dose interleukin-2, conventional chemotherapy, and biochemotherapy; and additional therapies currently under investigation in the form of clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_provenance.
- NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion evidence source_evidence_literature NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_provenance.
- NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion SIO_000772 23244384 NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_provenance.
- NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion wasDerivedFrom befree-20150227 NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_provenance.
- NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_assertion wasGeneratedBy ECO_0000203 NP493191.RARANwDjBAVWOp4wNxWEox0iV_26ySEp1xiJO1rme-sOE130_provenance.